Differentiated Antibodies
Multispecifics Design
Trican Biotechnology focuses on the construct and development of innovative therapeutic modalities that address unmet medical needs.
History
Trican Biotechnology, founded in 2015, is designing antibodies based on in vitro and in silico tools for in vivo validation. Through open technology integration with our proprietary platform, Trican delivers differentiated antibodies to address disease setting across oncology, immunology, and ophthalmology.
We are actively partnering globally with antibody-drug conjugates (ADCs), drug delivery, and bispecific/multispecific innovators.
Vision
Innovation, Integrity, Compassion
Guided by the beliefs for innovation, integrity, and compassion for all humanity, Trican Biotechnology strives to continuously advance our antibody engineering platform for speed and quality. We are singularly focused on driving forward novel antibody-based innovations to clinical studies. No one company can do everything. Thus, we aim to create candidates in collaboration that address unmet medical needs, improve the quality of life for patients, and create value for all stakeholders in the innovation ecosystem.
Technologies
Briefly, Trican Biotechnology harvested and assembled tumor reactive B cell receptors sequences into our proprietary DART library ''Directed and Activated immune Response against Tumors/lesions''.
Next-gen sequencing revealed more than 200 billion binders from DART with fully-human immunogenetics after recombination. For discovery campaigns Trican applies our proprietary high-throughput selection SERA ''Serially Enriched Recombinant Antibodies'' methodology.
Binders or SERAbodies from DART library by Trican are selected based on diversity, specificity, developability, and finally affinity against targets of interest. Trican engineers can further format and characterize SERAbodies into IgG or multispecifics candidates with targeted functionalities for further clinical development.
Multiple patents have been granted based on SERAbodies raised by Trican.
SERAbody Platform
''Serially Enriched Recombinant Antibodies'' Platform
DART
''Directed Activated immune Response against Tumors/lesions'' B-Cell Receptor Library
SERA
''Serially Enriched Recombinant Antibodies'' High-Throughput Selection platform
Trican's Antibody Discovery Mapping
SERAbody Portfolio
Project
Indication
Status
Discovery
Lead Optimization
Preclinical
IND-enabling
Phase I
TRB-007
Bispecific
TRB-817
Bispecific
TRB-818
Undisclosed
TRB-303
IgG
TRB-826
IgG
TRB-824
Bispecific
TRB-301
Undisclosed
Ophthalmology
Ophthalmology
Confidential
Oncology
Oncology
Oncology
Nephrology
Optioned
Optioned
Partnered
Partnered
In Development
Partnered
Optioned
Ready
In Development
News
Press Release, Updates, Announments
Contact
Head Office
24F-7 No.99 Section1, Xintaiwu Road,
Xizhi District, New Taipei City, 221
Inquiries
For any inquiries, questions or commendations, please call: +886-2-2697-2685 or fill out the following form
Employment
To apply for a job with Trican Biotech,
please see detailed information on the 104 website: www.104.com.tw